Medtronic has announced the commencement of a clinical trial of an investigational surgical aortic heart valve made from bovine pericardial tissue.
Intended to replace a diseased, damaged or malfunctioning native or prosthetic aortic valve, the valve was recently implanted in its first US patient as part of the PERIGON trial, which will assess the product for its ease of implantation, durability and haemodynamic performance.
“Medtronic has commenced a global clinical study of a new investigational pericardial surgical aortic heart valve.“
It has been designed with a low profile and interior-mounted leaflets to allow the passage of blood through the heart, thus lessening the risk of coronary obstruction. Moreover, the valve has been optimised to allow for future transcatheter aortic valve-in-valve interventions.
The PERIGON trial will study up to 650 patients at as many as 40 sites across Europe, the US and Canada.
Rhonda Robb, vice-president and general manager of heart valve therapies at Medtronic, said: "We are pleased with the progress of the trial thus far and the overall reception to this next-generation aortic valve."
Earlier this month, the company expanded its product range with the US launch of its new Anterior Cervical Fusion System, designed for the treatment of single-level cervical disc disease.See all the latest jobs in Medical Devices